JUL 8 9 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 1 5 2002

In re the application of: Maria Glucksmann et al.

Serial No.: 10/077698

Filed: February 13, 2002

For: 14273 RECEPTOR, A NOVEL G-PROTEIN

COUPLED RECEPTOR

Attorney Docket No.: MNI-204CP2DV1

Group Art Unit: 1646

Examiner: Brannock, M.

Commissioner for Patents Washington, D.C. 20231

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

 $\sqrt{0173},2002$

Maria C. Laccotripe, Ph.D., Limited Recognition Under 37 CFR §10 9(b)

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their attorney are aware of the following patents, publications or other information, which are cited on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these forms for the Examiner's consideration.

The present application is a divisional application of application no. 09/261,599 filed on February 26, 1999 (Atty. Docket No. MNI-204CP2), Pending, which in turn is a continuation-in part of copending U.S. Patent Application Serial No. 09/223,538, filed December 30, 1998, and entitled

Serial Number: 10/077698 Page -2- Group

Group Art Unit: 1646

part of copending U.S. Patent Application Serial No. 09/107,761, filed June 30, 1998, and entitled "14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR". All references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of these references are not enclosed herewith, but will be provided upon request.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted, LAHIVE & COCKFIELD, LLP

Maria C. Laccotripe, Ph.D. Attorney for Applicant

Limited Recognition Under 37 CFR \$10.9(b)

28 State Street Boston, MA 02109 (617) 227-7400

Date: 30143 2002

GAD/AEM/MCL/krj

Enclosures

APPLICANT	FACSIMILE	ОF	FOR M	PTO-1449	
RFV 7-80					

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY DOCKET NO	
MNI-057CP2DV1	

APPLICANT

10/077698

LIST OF PUBLICATIONS CITED BY APPLICANT

(Use several sheets if necessary)

Maria Glucksmann et al.

February 13, 2002 1646

U.S. PATENT DOCUMENTS

- EXAMINES		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	5,576,296	11/96	Barfai et al.	514	13	
	A2	5,756,460	05/98	Evans et al.	514	12	

FOREIGN PATENT DOCUMENTS

ſ		ODCUMENT NUMBER	DATE	Canter	CUASC	SURCLASS	TRANSLATION
-	 A 3	WO 94/01548 A2	01/94	PCT	-		YES NO
ŀ	A4	WO 94/01348 A2	07/99	PCT			ECHIVED
ŀ	 A 5	WO 98/15570 A1	04/98	PCT			UL 1 3 2002
įΪ	A 6	WO 99/38972 A2	01/99	PCT			
	A 7	WO 99/33982 A2	07/99	PCT		IEUm (ENTER 1600/2900
	A8	WO 00/00611 A2	01/00	PCT			

	OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)					
A9	BLAST Search vs. SwissProt, Genbank, Dbest and Patents Databases.					
A10	EMBL Accession No. AA030752 for mi31h04.r1 Soares mouse embryo NbME13.5 14.5 Mus musculus cDNA clone IMAGE:465175 5', mRNA sequence.					
A11	EMBL Accession No. AA413234 for ve94g10.r1 Knowles Solter mouse blastocyst B1 Mus musculus cDN/clone IMAGE:833922 5' similar to gb:X71129 ELECTRON TRANSFER FLAVOPROTEIN BETA-SUBUNIT (HUMAN);, mRNA sequence.					
A12	SwissProt Accession No. P41145, sequence alignment.					
A13	Bowie, J.U. et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <i>Science</i> . 1990 Mar 16; 247(4948):1306-10. Bowles, K.R. et al., "Genomic characterization of the human peptidyl-prolyl-cis-trans-isomerase, mitochondrial precursor gene: assessment of its role in familial dilated cardiomyopathy," <i>Hum Genet</i> . 1999 Dec; 105(6):582-6. Brown J.H. et al., "Pathways and roadblocks in muscarinic receptor-mediated growth regulation," <i>Life Sci</i> . 1997; 60(13-14):1077-84.					
A14						
A15						
A16 Chatelain et al., "Cardiac Ischaemia: Possibilities for Future Drug Therapy," Eur. J. Med. Che 32:687-707.						
A17	Glennon, P.E. et al., "Cellular mechanisms of cardiac hypertrophy," <i>Br Heart J.</i> 1995 Jun;73(6):496-9.					
xaminer	Date Considered					
Examiner	Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next					

communication to applicant.

COPY OF PAPERS
PRIGINALLY FILED

		THE OF FORM BYO LARD			Sheet 2 of 2						
APPLICANT FACSIMILE OF FORM PTO-1449 US DEPARTMENT OF COMMERCE REV 7.80 PATENT AND TRADEMARK OFFICE			MNI-057CP2DV	1	10/077698		(_				
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)					Maria Glucksm		F 7				
				FILING DATE February 13, 20	02	1646	100	1500			
(Use several sheets if necessary) Maria Glucksmann et al. FILING DATE FEBRUARY 13, 2002 1646 U.S. PATENT DOCUMENTS U.S. PATENT DOCUMENTS PARE CLASS SUBCLASS FILING DATE FEAPPROPRIATE											
CIMMAL EXAMPLER		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING (IF APPROI			
	-										
			FORE	EIGN PATENT DO	CUMENTS		,				
		DOCUMENT NUMBER	DATE		CONTRI	CLASS	SUBCLASS	TRANSL YES	ATION NO		
	B2 B3 B4 B5 B6	MacLellan, W. Circ Res. 1997 Mills, A. et al., Biotechnol. 19 Ngo, J.T., "Con Protein Folding Boston, 1994. Oliveira, L. et a of Computer-A Stadel, J.M., "C Trends Pharm	 1993;6(7):488-97. MacLellan, W.R. et al., "Death by design. Programmed cell death in cardiovascular biology and disease," <i>Circ Res.</i> 1997 Aug;81(2):137-44. Mills, A. et al., "Orphan seven transmembrane domain receptors: reversing pharmacology," <i>Trends Biotechnol.</i> 1994 Feb;12(2):47-9. Ngo, J.T., "Computational Complexity, Protein Structure Prediction and the Levinthal Paradox," in <i>The Protein Folding Problem and Tertiary Structure Predictions.</i> K. Merz and S. Legrand, Eds. Brikhauser, Boston, 1994. Oliveira, L. et al., "A common Motif in G-Protein-Coupled Seven Transmembrane Helix Receptors," <i>Journal of Computer-Aided Molecular Design.</i> 1993; 7(6):649-58. Stadel, J.M., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery," <i>Trends Pharmacol Sci.</i> 1997 Nov;18(11):430-7. 								
	B8				proteins," Biochem and cardiac hypertr	·			3):33-		
				· · · · · · · · · · · · · · · · · · ·					<u> </u>		
Examin	er			1	Date Considered						